Investing.com - Financial Markets Worldwide
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Sanofi Q3 top line up 3%; rare disease product sales up 14%; net income up 3%; shares up 8% premarket

Published 10/28/2016, 07:23 AM
Sanofi Q3 top line up 3%; rare disease product sales up 14%; net income up 3%; shares up 8% premarket
SASY
-
  • Sanofi (PA:SASY) Q3 results (€M): Total Sales: 9,652 (+3.0%); Genzyme: 1,270 (+16.9%); Diabetes and Cardiovascular: 1,585 (-2.5%); General Medicines & Emerging Markets: 4,370 (-2.4%); Sanofi Pasteur (Vaccines): 1,803 (+14.4%); Merial (Animal Health): 624 (+4.0%).
  • Sales by Franchise: Specialty Care: 1,517 (+18.5%); Diabetes & Cardiovascular: 1,929 (+0.3%); Established Products: 2,535 (-7.4%); Consumer Healthcare (CHC): 791 (-1.2%); Generics: 453 (+1.3%); Animal Health: 624 (+4.0%).
  • Rare Disease Product Sales: 708 (+14.3%); Cerezyme: 183 (+1.6%); Myozyme/Lumizyme: 185 (+16.0%); Fabrazyme: 176 (+20.4%).
  • Multiple Sclerosis Product Sales: 446 (+54.3%); Aubagio: 334 (+49.8%); Lemtrada: 112 (+69.1%).
  • Oncology Product Sales: 363 (-2.4%).
  • Diabetes Product Sales: 1,805 (-1.5%); Lantus: 1,391 (-9.8%); Toujeo: 167 (+265.2%).
  • Established Products Sales: 2,535 (-7.4%): Plavix: 401 (-9.9%); Lovenox: 404 (-4.0%); Renvela/Renagel: 245 (+2.9%).
  • Influenza Vaccines: 989 (+34.6%).
  • Net Income: 1,674 (+2.8%); EPS: 1.30 (+4.0%).
  • 2016 Guidance: EPS Growth: 3 - 5%.
  • Company plans to divest EU generics business within 12 - 24 months. CHC asset swap with Boehringer Ingelheim should close by year end.
  • Share are up 8% premarket on average volume.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.